Safety Shot Announces Notice of Allowance for New Patent to Secure IP and Enforce Clinically Backed Claims

Rhea-AI Summary

Safety Shot, Inc. (Nasdaq: SHOT) has announced a Notice of Allowance for a new U.S. patent covering its latest clinically-backed formula. This patent strengthens the company's portfolio of formulations designed to rapidly reduce blood alcohol content (BAC). Safety Shot's COO, David Sandler, highlighted this as a significant milestone in the company's mission to lead a new category addressing alcohol-related problems.

The patent supports Safety Shot's competitive advantage, including faster alcohol removal, improved cognitive ability, and reduced impairment. It also allows the company to enforce specific marketplace claims and solidifies its position as a leader in rapid alcohol reduction. CEO Jarret Boon emphasized the patent's role in supporting their industry-leading clinical findings and commitment to consumer solutions.

Positive

• Received Notice of Allowance for a new U.S. patent covering latest formula
• Strengthens intellectual property portfolio in rapid alcohol reduction
• Supports claims of faster alcohol removal and improved cognitive ability
• Allows enforcement of specific marketplace claims
• Solidifies position as leader in rapid alcohol reduction category

Negative

• None.

Insights

Medical Research Analyst

The Notice of Allowance for Safety Shot's new patent is a significant development in the alcohol reduction market. This patent strengthens their intellectual property portfolio and supports their claims of rapidly reducing Blood Alcohol Content (BAC). The company's focus on clinical backing and patent protection sets a high bar for potential competitors.

From a medical perspective, the ability to lower BAC in as little as 30 minutes could have substantial implications for public health and safety. However, it's important to note that while this product may reduce BAC, it doesn't necessarily eliminate all effects of alcohol or guarantee sobriety. Further independent studies would be beneficial to validate the product's efficacy and safety profile.

The company's commitment to R&D and expanding their product formats is promising, but investors should closely monitor future clinical trials and regulatory approvals to fully assess the product's potential impact on alcohol-related health issues.

Market Research Analyst

Safety Shot's patent allowance represents a strategic move to dominate the nascent 'rapid alcohol reducer' market. By securing intellectual property rights, the company is positioning itself as the pioneer in this new category, potentially creating significant barriers to entry for competitors.

The market potential for such a product could be substantial, considering the global prevalence of alcohol consumption and related issues. However, consumer adoption will depend on factors such as pricing, accessibility and public perception. Safety Shot's success will hinge on effective marketing strategies and educating consumers about the product's benefits and limitations.

Investors should watch for partnerships with bars, restaurants, or ride-sharing services, as these could significantly boost product visibility and sales. Additionally, keep an eye on regulatory responses and potential pushback from alcohol industry stakeholders.

Legal Expert

The Notice of Allowance for Safety Shot's new patent is a crucial legal milestone. It not only protects their intellectual property but also provides a strong foundation for enforcing their claims against potential infringers. This legal protection is particularly valuable in a new and potentially lucrative market segment.

However, investors should be aware that patent protection doesn't guarantee market success. The company may face challenges in regulatory compliance, particularly with food and drug administrations worldwide. The product's claims of reducing BAC and improving cognitive ability post-alcohol consumption could attract scrutiny from regulatory bodies.

Furthermore, the company's assertive stance against "inferior products" suggests a readiness for potential legal battles. While this demonstrates confidence, it also implies a risk of future litigation costs. Monitoring the company's legal strategies and any challenges to their patents will be important for assessing long-term viability.

New Patent is Added to the Company’s Portfolio of Formulations that Rapidly Reduce Blood Alcohol Content

JUPITER, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or “the Company”), a wellness company behind the world's first rapid alcohol reducer that lowers blood alcohol content (“BAC”) by supporting its metabolism in as little as 30 minutes, has announced the Notice of Allowance of for a U.S. patent that covers its newest clinically-backed formula.

“This latest patent marks a significant milestone in Safety Shot’s quest to lead a brand-new category that the Company has created to solve alcohol related problems,” stated Safety Shot COO and co-owner of the patent, David Sandler.

The Company’s family of patents aims to corroborate Safety Shot’s competitive advantage in the market which includes being faster at removing alcohol, improving cognitive ability, and reducing impairment by supporting the metabolism of alcohol. The latest patent continues to advance an exciting new category of functionality.

“The patent locks up our IP and further separates us from the pack as the only the group that has been able prove that Safety’s Shot revolutionary formula can dramatically reduce blood alcohol and reduce the build-up toxins associated with alcohol consumption rapidly. This patent helps solidify Safety Shot as the uncontested world leader in making people feel better faster,” continued Sandler, who co-invented the Safety Shot wellness product.

“The patent allows Safety Shot to exercise authority over specific claims in the marketplace. It further proves our commitment to finding solutions for consumers while taking a hard stance against other companies that enter the category with inferior products. Our patents provide enforceable support to our industry-leading clinical findings,” noted Safety Shot CEO and patent co-owner, Jarret Boon.

As part of the Company’s efforts to be recognized as the world leader in combating the ill effects of alcohol, the team at Safety Shot is committed to advancing its science through its robust R&D platform that offers a variety of formats using its clinically proven, patented formula.

About Safety Shot, Inc.

Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot’s ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled “Risk Factors” in Safety Shot’s Form 10-Q for the fiscal year ended June 30, 2024, filed with the Securities and Exchange Commission on August 15, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.

Media and Investor Contact:
Autumn Communications
Jess Weinberger
Phone: 201-213-3239
Email: shot@autumncommunications.com

Investor Relations
Medon Michaelides
Phone: 561-244-7100
Email: investors@drinksafetyshot.com

FAQ

What is the latest patent announcement from Safety Shot (SHOT)?

Safety Shot (SHOT) announced a Notice of Allowance for a new U.S. patent covering its latest clinically-backed formula for rapid alcohol reduction.

How does the new patent benefit Safety Shot (SHOT)?

The new patent strengthens Safety Shot's intellectual property, supports its competitive advantage, and allows the company to enforce specific marketplace claims related to rapid alcohol reduction.

What are the key features of Safety Shot's (SHOT) alcohol reduction formula?

Safety Shot's formula claims to lower blood alcohol content in as little as 30 minutes, improve cognitive ability, and reduce impairment by supporting alcohol metabolism.

Who are the key figures mentioned in Safety Shot's (SHOT) patent announcement?

David Sandler, COO and co-owner of the patent, and Jarret Boon, CEO and patent co-owner, were mentioned as key figures in Safety Shot's patent announcement.